S-adenosylhomocysteine hydrolase deficiency
S-aden-o-syl-ho-mo-cys-teine hy-dro-lase deficiency
Also known as: AdoHcyase deficiency, SAHH deficiency
At a Glance
What is S-adenosylhomocysteine hydrolase deficiency?
S-adenosylhomocysteine hydrolase deficiency is a rare genetic disorder that affects the body's ability to metabolize certain amino acids. It primarily impacts the liver, cardiovascular system, and neurological functions. The condition is caused by mutations in the AHCY gene, leading to an accumulation of S-adenosylhomocysteine. Over time, this accumulation can cause liver damage, developmental delays, and cardiovascular issues. Early symptoms may include feeding difficulties and developmental delays, while later symptoms can involve liver disease and neurological impairments. Early diagnosis is critical to manage symptoms and prevent severe complications. The disorder can place a significant emotional and financial burden on families due to the need for ongoing medical care and dietary management. Prognosis varies, with some individuals experiencing severe complications, while others may have a milder course. Daily life for affected individuals often involves regular medical monitoring and adherence to a specialized diet. Supportive therapies can help manage symptoms and improve quality of life. Genetic counseling is recommended for families to understand the inheritance pattern and risks for future pregnancies. Research is ongoing to better understand the condition and develop more effective treatments.
Medical Definition
S-adenosylhomocysteine hydrolase deficiency is a metabolic disorder characterized by the inability to properly metabolize S-adenosylhomocysteine due to mutations in the AHCY gene. Pathologically, this leads to the accumulation of S-adenosylhomocysteine, which can interfere with methylation processes in the body. Histologically, liver biopsies may show signs of liver damage and fibrosis. The disorder is classified under inborn errors of metabolism and is inherited in an autosomal recessive manner. Epidemiologically, it is an extremely rare condition with a prevalence of approximately 1 in 1,000,000. The disease course can vary, with some individuals experiencing severe complications, while others may have a milder phenotype.
S-adenosylhomocysteine hydrolase deficiency Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Liver dysfunction in S-adenosylhomocysteine hydrolase deficiency often presents as elevated liver enzymes and hepatomegaly. The biological mechanism involves the accumulation of S-adenosylhomocysteine, which disrupts methylation processes critical for liver function. Over time, this can lead to progressive liver damage and potentially liver failure. This condition can severely affect daily life by causing fatigue and jaundice, and management may include dietary modifications and regular monitoring of liver function.
Developmental delay manifests as slower achievement of motor and cognitive milestones in children. It is caused by disrupted methylation affecting neural development due to the accumulation of S-adenosylhomocysteine. Without intervention, these delays may persist or worsen, impacting educational and social development. Early intervention programs and supportive therapies can help mitigate these effects and improve developmental outcomes.
Hypotonia presents as decreased muscle tone, leading to floppiness and reduced strength. It results from impaired neuromuscular function due to disrupted methylation pathways. Over time, hypotonia can lead to difficulties with movement and posture, affecting physical activities. Physical therapy and supportive care can help improve muscle tone and enhance mobility.
Common
Seizures in this condition are often generalized and can vary in frequency and severity. They are caused by abnormal neuronal excitability due to disrupted methylation and neurotransmitter imbalances. If untreated, seizures can become more frequent and severe, impacting quality of life. Antiepileptic medications and regular neurological assessments are crucial for management.
Failure to thrive is characterized by poor weight gain and growth in children. It results from metabolic imbalances and nutritional deficiencies due to impaired liver function. Over time, this can lead to stunted growth and developmental issues. Nutritional support and monitoring are essential to address growth concerns and improve health outcomes.
Hyperhomocysteinemia is an elevated level of homocysteine in the blood, detectable through blood tests. It occurs due to the accumulation of S-adenosylhomocysteine, which inhibits the conversion of homocysteine to methionine. Persistent hyperhomocysteinemia can increase the risk of cardiovascular issues. Dietary management and supplementation with vitamins like B6, B12, and folate can help reduce homocysteine levels.
Less Common
Atherosclerotic calcification involves the hardening and narrowing of arteries due to calcium deposits. It is linked to epigenetic changes and metabolic disturbances caused by S-adenosylhomocysteine accumulation. Over time, this can lead to cardiovascular complications such as heart attacks and strokes. Lifestyle modifications and medications to manage cholesterol and blood pressure can help mitigate risks.
Retinopathy presents as vision problems due to damage to the retina. It is associated with metabolic disturbances and oxidative stress from disrupted methylation. Progressive retinopathy can lead to vision loss if untreated. Regular ophthalmologic evaluations and appropriate interventions are necessary to preserve vision and manage symptoms.
What Causes S-adenosylhomocysteine hydrolase deficiency?
S-adenosylhomocysteine hydrolase deficiency is caused by mutations in the AHCY gene, located on chromosome 20q11.22. The AHCY gene encodes the enzyme S-adenosylhomocysteine hydrolase, which is crucial for the conversion of S-adenosylhomocysteine (SAH) to homocysteine and adenosine. Mutations in the AHCY gene lead to structural changes in the enzyme, impairing its ability to catalyze this reaction. As a result, SAH accumulates inside the cell, inhibiting methylation reactions by acting as a potent feedback inhibitor of methyltransferases. This disruption in methylation affects various cellular processes, including DNA, RNA, and protein methylation, leading to widespread epigenetic changes. Organelle dysfunction, particularly in the mitochondria and endoplasmic reticulum, arises due to altered methylation of proteins involved in their function. Neighboring cells and tissues experience altered signaling and metabolic stress, contributing to tissue-specific manifestations. Neuroinflammation may be triggered as a secondary response to cellular stress and damage, exacerbating neuronal injury. White matter degeneration occurs due to impaired myelin synthesis and maintenance, driven by disrupted methylation of myelin-related proteins. Symptoms appear in a pattern reflecting the most affected tissues, such as the liver, brain, and cardiovascular system, due to their high reliance on methylation processes. Disease severity varies between patients due to differences in residual enzyme activity, genetic background, and environmental factors. The accumulation of SAH and subsequent methylation defects can also lead to immune dysregulation, contributing to systemic manifestations. In some cases, asymptomatic presentations occur, possibly due to compensatory metabolic pathways or less severe mutations. The variability in clinical presentation is also influenced by the presence of modifying genes and epigenetic factors. Understanding the precise molecular mechanisms and pathways affected by AHCY mutations remains an area of active research.
How is S-adenosylhomocysteine hydrolase deficiency Diagnosed?
Typical age of diagnosis: S-adenosylhomocysteine hydrolase deficiency is typically diagnosed in infancy or early childhood, often following the presentation of developmental delays or unexplained liver dysfunction. Diagnosis may also occur later in life if symptoms are mild or atypical, as seen in some asymptomatic pediatric cases.
The clinician looks for signs of developmental delay, liver dysfunction, and possible neurological symptoms. A detailed family history is important to identify any genetic predisposition or similar conditions in relatives. Physical examination may reveal hepatomegaly or other signs of liver involvement. This step helps to determine the need for further biochemical and genetic testing.
Ultrasound is the primary imaging modality used to assess liver size and structure. Specific abnormalities such as hepatomegaly or liver lesions may be visible. These findings can support the diagnosis of liver involvement in the condition. Imaging helps exclude other causes of liver disease, such as biliary atresia or metabolic liver disorders.
Blood tests are ordered to measure levels of S-adenosylhomocysteine and homocysteine. Elevated levels of these biomarkers are indicative of the deficiency. Abnormal results prompt further investigation into metabolic pathways. Laboratory findings guide the decision to proceed with genetic testing.
The AHCY gene is sequenced to identify mutations responsible for the deficiency. Common mutation types include missense, nonsense, and splice site mutations. Genetic testing confirms the diagnosis and helps differentiate it from other metabolic disorders. Results are crucial for family counseling and assessing recurrence risk.
S-adenosylhomocysteine hydrolase deficiency Treatment Options
Betaine is an osmolyte and methyl donor used to lower homocysteine levels. It works by donating a methyl group to homocysteine, converting it to methionine. Clinical evidence shows betaine can reduce homocysteine levels and improve liver function. However, its efficacy in preventing neurological symptoms is limited. Side effects may include gastrointestinal discomfort and elevated serum methionine.
Techniques include motor skill exercises and cognitive development activities. The goal is to enhance physical and mental development in affected children. Sessions are typically conducted 2-3 times a week for 30-60 minutes. Outcomes are measured by improvements in motor skills and cognitive assessments. Long-term benefits include better quality of life and increased independence.
Indicated for severe liver dysfunction or failure unresponsive to medical therapy. The procedure involves replacing the diseased liver with a healthy donor liver. Benefits include improved liver function and potential resolution of metabolic abnormalities. Surgical risks include rejection, infection, and complications from immunosuppression. Post-operative care requires lifelong monitoring and medication adherence.
The team includes hepatologists, neurologists, dietitians, and genetic counselors. Interventions focus on managing symptoms, optimizing nutrition, and providing genetic counseling. Psychosocial support strategies involve counseling and support groups for families. Education is provided on disease management and lifestyle adaptations. Long-term monitoring includes regular follow-ups and adjustment of treatment plans as needed.
When to See a Doctor for S-adenosylhomocysteine hydrolase deficiency
- Severe liver dysfunction — this is an emergency because it can lead to liver failure and requires immediate medical intervention.
- Neurological deterioration — sudden changes in mental status or seizures indicate potential brain involvement and need urgent evaluation.
- Severe cardiovascular symptoms — such as chest pain or shortness of breath, which may indicate atherosclerotic complications requiring emergency care.
- Progressive vision loss — this could signify ocular involvement and should prompt a specialist evaluation.
- Persistent fatigue — may indicate metabolic imbalance or liver dysfunction, requiring further investigation.
- Unexplained weight loss — could be a sign of metabolic issues or organ dysfunction, warranting medical assessment.
- Mild fatigue — monitor energy levels and maintain a balanced diet, consult a doctor if it worsens.
- Mild gastrointestinal discomfort — keep track of symptoms and dietary triggers, seek advice if persistent.
S-adenosylhomocysteine hydrolase deficiency — Frequently Asked Questions
Is this condition hereditary?
S-adenosylhomocysteine hydrolase deficiency is inherited in an autosomal recessive pattern. This means both parents must be carriers for a child to be affected, with a 25% chance for each child. De novo mutations are rare in this condition. Carrier status typically does not affect health but can have implications for family planning. Genetic counseling is recommended for families to understand risks and carrier testing options.
What is the life expectancy for someone with this condition?
Life expectancy varies based on the age of onset and severity of symptoms. Early diagnosis and management can improve outcomes significantly. Mortality is often due to complications such as liver failure or cardiovascular issues. Treatment can extend survival and improve quality of life by managing symptoms and complications. Realistic expectations should include regular monitoring and proactive management of health.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves biochemical tests to detect elevated S-adenosylhomocysteine levels and genetic testing to confirm mutations. The time from first symptoms to diagnosis can vary, often taking months due to the rarity of the condition. Specialists such as geneticists and hepatologists are typically involved. Delayed diagnosis is common due to nonspecific symptoms and lack of awareness. Confirmation is achieved through genetic testing and metabolic profiling.
Are there any new treatments or clinical trials available?
Research is ongoing, with promising studies on betaine supplementation and potential gene therapy approaches. ClinicalTrials.gov is a resource for finding trials, and patients should discuss eligibility with their doctor. Questions to ask include potential benefits, risks, and trial locations. The timeline for new treatments depends on trial outcomes and regulatory approvals. Staying informed through medical updates and research publications is advisable.
How does this condition affect daily life and activities?
The condition can impact mobility and self-care, particularly if neurological or liver symptoms are present. Educational accommodations may be necessary for children with cognitive or physical challenges. Social and emotional support is crucial due to the chronic nature of the disease. Family burden can be significant, requiring access to resources and support networks. Adaptations such as dietary management and therapy can help improve quality of life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Asymptomatic pediatric presentation of S-adenosylhomocysteine hydrolase deficiency.
Lipari Pinto P, Dixon M, Sudhakar S et al. · JIMD Rep · 2024 · PMID: 39512434
- 2.Epigenetic Upregulation of H19 and AMPK Inhibition Concurrently Contribute to S-Adenosylhomocysteine Hydrolase Deficiency-Promoted Atherosclerotic Calcification.
Dai X, Liu S, Cheng L et al. · Circ Res · 2022 · PMID: 35410483
- 3.Betaine Supplementation Attenuates S-Adenosylhomocysteine Hydrolase-Deficiency-Accelerated Atherosclerosis in Apolipoprotein E-Deficient Mice.
Dai X, Liu S, Cheng L et al. · Nutrients · 2022 · PMID: 35277077
- 4.Effects of S-Adenosylhomocysteine Hydrolase Downregulation on Wnt Signaling Pathway in SW480 Cells.
Pavičić I, Rokić F, Vugrek O · Int J Mol Sci · 2023 · PMID: 38003292
- 5.The biochemical profile and dietary management in S-adenosylhomocysteine hydrolase deficiency.
Huang Y, Chang R, Abdenur JE · Mol Genet Metab Rep · 2022 · PMID: 35789945
- 6.Adult-onset liver disease and hepatocellular carcinoma in S-adenosylhomocysteine hydrolase deficiency.
Stender S, Chakrabarti RS, Xing C et al. · Mol Genet Metab · 2015 · PMID: 26527160
- 7.CRB1-related retinopathy overlapping the ocular phenotype of S-adenosylhomocysteine hydrolase deficiency.
Grudzinska Pechhacker MK, Di Scipio M, Vig A et al. · Ophthalmic Genet · 2020 · PMID: 32689861
- 8.S-Adenosylhomocysteine hydrolase (AdoHcyase) deficiency: enzymatic capabilities of human AdoHcyase are highly effected by changes to codon 89 and its surrounding residues.
Beluzić R, Cuk M, Pavkov T et al. · Biochem Biophys Res Commun · 2008 · PMID: 18211827
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-05-31